Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. more
Time Frame | ABBV | Sector | S&P500 |
---|---|---|---|
1-Week Return | -17.3% | -5.55% | -0.8% |
1-Month Return | -14.01% | -7.2% | 2.36% |
3-Month Return | -14.69% | -7.12% | 7.31% |
6-Month Return | 0.73% | -2.98% | 12.04% |
1-Year Return | 19.91% | 10.85% | 32.05% |
3-Year Return | 41.21% | 6.66% | 26.94% |
5-Year Return | 86.16% | 45.54% | 90.46% |
10-Year Return | 153.67% | 109.88% | 191.06% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 33.27B | 45.80B | 56.20B | 58.05B | 54.32B | [{"date":"2019-12-31","value":57.3,"profit":true},{"date":"2020-12-31","value":78.9,"profit":true},{"date":"2021-12-31","value":96.8,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":93.56,"profit":true}] |
Cost of Revenue | 7.44B | 15.39B | 17.45B | 17.41B | 8.78B | [{"date":"2019-12-31","value":42.64,"profit":true},{"date":"2020-12-31","value":88.2,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.82,"profit":true},{"date":"2023-12-31","value":50.33,"profit":true}] |
Gross Profit | 25.83B | 30.42B | 38.75B | 40.64B | 45.54B | [{"date":"2019-12-31","value":56.72,"profit":true},{"date":"2020-12-31","value":66.79,"profit":true},{"date":"2021-12-31","value":85.1,"profit":true},{"date":"2022-12-31","value":89.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 77.64% | 66.41% | 68.96% | 70.00% | 83.84% | [{"date":"2019-12-31","value":92.61,"profit":true},{"date":"2020-12-31","value":79.21,"profit":true},{"date":"2021-12-31","value":82.25,"profit":true},{"date":"2022-12-31","value":83.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 12.46B | 17.86B | 19.86B | 21.83B | 21.15B | [{"date":"2019-12-31","value":57.08,"profit":true},{"date":"2020-12-31","value":81.81,"profit":true},{"date":"2021-12-31","value":91.02,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.88,"profit":true}] |
Operating Income | 12.98B | 11.36B | 17.92B | 18.12B | 12.76B | [{"date":"2019-12-31","value":71.66,"profit":true},{"date":"2020-12-31","value":62.72,"profit":true},{"date":"2021-12-31","value":98.93,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":70.41,"profit":true}] |
Total Non-Operating Income/Expense | (6.07B) | (10.24B) | (7.32B) | (6.68B) | (8.19B) | [{"date":"2019-12-31","value":-606600000000,"profit":false},{"date":"2020-12-31","value":-1024500000000,"profit":false},{"date":"2021-12-31","value":-731900000000,"profit":false},{"date":"2022-12-31","value":-668400000000,"profit":false},{"date":"2023-12-31","value":-819100000000,"profit":false}] |
Pre-Tax Income | 8.43B | 3.40B | 12.99B | 13.48B | 6.25B | [{"date":"2019-12-31","value":62.52,"profit":true},{"date":"2020-12-31","value":25.21,"profit":true},{"date":"2021-12-31","value":96.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":46.38,"profit":true}] |
Income Taxes | 544.00M | 1.22B | 1.44B | 1.63B | 1.38B | [{"date":"2019-12-31","value":33.33,"profit":true},{"date":"2020-12-31","value":75,"profit":true},{"date":"2021-12-31","value":88.24,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.38,"profit":true}] |
Income After Taxes | 7.88B | 2.17B | 11.55B | 11.85B | 4.87B | [{"date":"2019-12-31","value":66.54,"profit":true},{"date":"2020-12-31","value":18.35,"profit":true},{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true}] |
Income From Continuous Operations | 7.88B | 4.62B | 11.55B | 11.85B | 4.87B | [{"date":"2019-12-31","value":66.54,"profit":true},{"date":"2020-12-31","value":39.02,"profit":true},{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 7.88B | 4.62B | 11.54B | 11.84B | 4.86B | [{"date":"2019-12-31","value":66.59,"profit":true},{"date":"2020-12-31","value":39,"profit":true},{"date":"2021-12-31","value":97.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.09,"profit":true}] |
EPS (Diluted) | 8.94 | 10.51 | 12.68 | 13.87 | 11.11 | [{"date":"2019-12-31","value":64.46,"profit":true},{"date":"2020-12-31","value":75.78,"profit":true},{"date":"2021-12-31","value":91.42,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.1,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
ABBV | |
---|---|
Cash Ratio | 0.17 |
Current Ratio | 0.65 |
Quick Ratio | 0.54 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ABBV | |
---|---|
ROA (LTM) | 7.72% |
ROE (LTM) | 56.41% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ABBV | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.96 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.04 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ABBV | |
---|---|
Trailing PE | 59.10 |
Forward PE | 14.31 |
P/S (TTM) | 5.40 |
P/B | 49.70 |
Price/FCF | 58 |
EV/R | 6.55 |
EV/Ebitda | 19.95 |
PEG | 0.40 |
AbbVie Inc (ABBV) share price today is $164.99
Yes, Indians can buy shares of AbbVie Inc (ABBV) on Vested. To buy AbbVie Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ABBV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of AbbVie Inc (ABBV) via the Vested app. You can start investing in AbbVie Inc (ABBV) with a minimum investment of $1.
You can invest in shares of AbbVie Inc (ABBV) via Vested in three simple steps:
The 52-week high price of AbbVie Inc (ABBV) is $207.32. The 52-week low price of AbbVie Inc (ABBV) is $132.3.
The price-to-earnings (P/E) ratio of AbbVie Inc (ABBV) is 59.5629
The price-to-book (P/B) ratio of AbbVie Inc (ABBV) is 49.70
The dividend yield of AbbVie Inc (ABBV) is 3.83%
The market capitalization of AbbVie Inc (ABBV) is $302.34B
The stock symbol (or ticker) of AbbVie Inc is ABBV